SCHEMBL2942484

SCHEMBL2942484

CSCCC1NC2(CCN(C(=O)c3ccc([N+](=O)[O-])cc3)CC2)N(CC(=O)O)C1=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
KDM4E B2RXH2 2/20 0.41
GALR3 O60755 1/20 0.41
HTT P42858 1/20 0.41
ATM Q13315 1/20 0.40
KMT2A Q03164 5/20 0.38
MEN1 O00255 2/20 0.38
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA7 P43166 1/20 0.38
CA9 Q16790 1/20 0.38
CA14 Q9ULX7 1/20 0.38
LMNA P02545 1/20 0.38
POLB P06746 1/20 0.37
HSD11B1 P28845 1/20 0.37
MGLL Q99685 1/20 0.37
PKM P14618 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2943359 0.86 HPGD (0.41) SMN1; SMN2HTTKMT2AMEN1ALDH1A1
SCHEMBL2943345 0.85 MEN1 (0.40) KMT2AMEN1HSD11B1MGLLALDH1A1
SCHEMBL1801867 0.84 ATM (0.41) SMN1; SMN2NPC1RAB9AKDM4EGALR3
SCHEMBL2936852 0.83 HRH3 (0.44) HSD11B1MGLL
SCHEMBL2943567 0.80 PROKR1 (0.36) HTTKMT2AMEN1MGLLALDH1A1
SCHEMBL2942272 0.79 GAA (0.40) SMN1; SMN2HTTALDH1A1
SCHEMBL1800242 0.78 KDM4E (0.44) SMN1; SMN2KDM4EHTTKMT2ACA12
SCHEMBL3997851 0.78 ATM (0.43) SMN1; SMN2NPC1RAB9AKDM4EGALR3
SCHEMBL1800410 0.78 OPRM1 (0.32) HTTALDH1A1
SCHEMBL2942901 0.78 CHRNA4 (0.39) HTTKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1730147-B1 SUBSTITUTED 1,4,8-TRIAZASPIRO[4,5]DECAN-2-ON COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY GRUENENTHAL GMBH (DE) 2010-02-03 EP claimed
US-20070015784-A1 Subsitituted 1,4,8- triazaspiro [4,5]decan-2-one compounds GRUENENTHAL GMBH (DE) 2007-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015784-A1 Subsitituted 1,4,8- triazaspiro [4,5]decan-2-one compounds SI, SSTR4, SLC10A2 SMN1; SMN2 2139/4885NPC1 479/4885RAB9A 2159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.